TECH Logo

Bio-Techne Corporation (TECH) 

NASDAQ
Market Cap
$12.1B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
738 of 776
Rank in Industry
407 of 433

Largest Insider Buys in Sector

TECH Stock Price History Chart

TECH Stock Performance

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and …

Insider Activity of Bio-Techne Corporation

Over the last 12 months, insiders at Bio-Techne Corporation have bought $0 and sold $2.29M worth of Bio-Techne Corporation stock.

On average, over the past 5 years, insiders at Bio-Techne Corporation have bought $105,765 and sold $45.9M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 300 shares for transaction amount of $105,765 was made by BAUMGARTNER ROBERT V () on 2022‑05‑10.

List of Insider Buy and Sell Transactions, Bio-Techne Corporation

2024-08-08Saledirector
16,000
0.0099%
$72.10$1.15M+0.50%
2024-05-14Saledirector
4,000
0.0025%
$83.84$335,377-10.55%
2024-03-07Saledirector
10,400
0.0066%
$76.98$800,627-3.85%
2023-08-30Saledirector
8,939
0.0057%
$80.32$717,959-10.75%
2023-07-21SaleChief Executive Officer
80,000
0.0503%
$88.36$7.07M-19.60%
2023-06-07SaleChief Executive Officer
322
0.0002%
$83.00$26,726-12.11%
2022-12-08SaleSVP - GENERAL COUNSEL
7,450
0.0048%
$82.12$611,810-4.32%
2022-08-10Sale
100
0.0003%
$374.89$37,490-14.58%
2022-06-07SaleCHIEF EXECUTIVE OFFICER
5,104
0.013%
$365.00$1.86M-10.27%
2022-06-07Sale
1,000
0.0025%
$364.31$364,310-10.27%
2022-05-10Purchase
300
0.0008%
$352.55$105,765-6.24%
2021-11-19SalePres. Diagnostics & Genom
500
0.0013%
$505.38$252,689-25.89%
2021-11-12SalePresident-Protein Sciences
27,159
0.069%
$504.00$13.69M-25.51%
2021-11-02SaleChief Financial Officer
200
0.0005%
$525.10$105,020-24.34%
2021-11-01SaleChief Financial Officer
8,822
0.0225%
$526.52$4.64M-27.41%
2021-10-29SaleChief Financial Officer
662
0.0017%
$525.23$347,704-27.12%
2021-10-28SaleChief Financial Officer
100
0.0003%
$525.18$52,518-25.88%
2021-09-22SalePres. Diagnostics & Genom
822
0.0021%
$529.04$434,871-24.44%
2021-09-07Saledirector
8,000
0.0203%
$509.98$4.08M-19.57%
2021-09-02SaleChief Financial Officer
10,000
0.0254%
$507.22$5.07M-18.94%

Insider Historical Profitability

15.55%
BAUMGARTNER ROBERT Vdirector
43401
0.0274%
$76.30615+12.2%
Kummeth Charles R.Chief Executive Officer
1258766
0.7934%
$76.30121+18.28%
OCONNELL HOWARD Vdirector
70000
0.0441%
$76.30115+32.95%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$1.29B11.618.27M+0.24%+$3.11M0.02
BlackRock$1.25B11.2617.75M-2.14%-$27.31M0.03
State Street$448.31M4.046.37M+0.64%+$2.87M0.02
T. Rowe Price$404.47M3.655.75M+92.11%+$193.93M0.05
Bamco$351.82M3.175M-6.61%-$24.9M0.94
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.